BioCentury
ARTICLE | Clinical News

Phase III of Bellerophon's INOpulse for PAH stopped for futility

August 10, 2018 6:42 PM UTC

Bellerophon Therapeutics Inc. (NASDAQ:BLPH) said a DMC recommended stopping for futility the Phase III INOvation-1 trial of INOpulse to treat pulmonary arterial hypertension (PAH).

A prespecified interim analysis of the first 75 patients who completed 16 weeks of treatment showed that the overall change on the primary endpoint of 6-minute walk distance (6MWD) was insufficient to support continuing the trial...